Form Type:  D
Filing Date:  5/19/2017 
CIK:  0001603454 
Address:  16305 36TH AVENUE N
City, State, Zip:  MINNEAPOLIS, Minnesota 55446 
Telephone:  763-392-0767 
Last Trade
Last Trade: 
0.02 (0.10%)  
Trade Time: 
10:20 AM EST  
Market Cap: 
Trade CELC now with 

© 2018  
Description of Business
We are a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. Our proprietary CELx diagnostic platform is the only commercially ready technology we are aware of that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that best treats it. We believe our CELx platform provides two important improvements over traditional molecular diagnostics. First, molecular diagnostics can only provide a snapshot of the genetic mutations present in a patient's tumor because they analyze dead cells. Using dead cells prevents molecular diagnostics from analyzing in real-time the dynamic cellular activities, known as cell signaling, that regulate cell proliferation or survival. Cancer can develop when certain cell signaling activity becomes abnormal.
Register and access this filing in: